Why the study?
Do anthracycline doses >= 270 mg/m(2) increase the risk of abnormalities of FS and afterload in childhood cancer survivors?
Do anthracycline doses >= 270 mg/m(2) increase the risk of abnormalities of FS and afterload in childhood cancer survivors?
Anthracycline doses >= 270 mg/m(2) identify childhood cancer survivors at greatest risk for late abnormalities in fractional shortening and afterload.
Childhood cancer survivors treated with anthracycline doses >or= 270 mg/m(2) are at greatest risk for abnormalities of FS and afterload.
No takes yet. Share an insight, caveat, or question.
Hudson et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: